Orvo Ast

Title: Orvo Ast: Innovator in Measles Virus Vaccine Development

Introduction

Orvo Ast is a notable inventor based in Pierrefonds, Canada. He has made significant contributions to the field of virology, particularly in the development of vaccines. His work has focused on creating an attenuated strain of the measles virus, which is crucial for vaccine production.

Latest Patents

Orvo Ast holds a patent for a strain of measles virus and the process of producing the same. This patent describes a method for producing an attenuated strain of the measles virus that is effective for vaccine development. The process begins with the Edmonston strain of measles virus, which undergoes multiple culture passages in various media. The final culture passage is taken and further cultured in primary fibroblast cultures of chicken embryos. The resulting clones of the virus are isolated, with a focus on those that are thermosensitive at temperatures between 32°C and 37°C. Among these, selections are made based on cytopathic effects, ultimately isolating the strain that shows the highest seroconversion in monkeys.

Career Highlights

Orvo Ast has worked at L'Institut Armand-Frappier, where he has contributed to important research in vaccine development. His innovative approach to producing an attenuated strain of the measles virus has the potential to enhance vaccine efficacy and safety.

Collaborations

Throughout his career, Orvo has collaborated with notable colleagues, including Robert Dubreuil, who is now deceased, and Vytautas Pavilanis. These collaborations have enriched his research and contributed to advancements in the field.

Conclusion

Orvo Ast's work in developing an attenuated strain of the measles virus represents a significant advancement in vaccine technology. His contributions continue to impact public health through improved vaccination strategies.